Pier 88 Investment Partners LLC Trims Stock Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Pier 88 Investment Partners LLC cut its stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 86.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 170,890 shares of the company's stock after selling 1,052,550 shares during the period. Pier 88 Investment Partners LLC owned about 0.28% of Health Catalyst worth $1,208,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Palogic Value Management L.P. purchased a new stake in shares of Health Catalyst in the 4th quarter valued at about $2,262,000. Fox Run Management L.L.C. acquired a new position in Health Catalyst during the fourth quarter worth approximately $216,000. American Century Companies Inc. lifted its stake in Health Catalyst by 1.8% in the fourth quarter. American Century Companies Inc. now owns 710,481 shares of the company's stock valued at $5,023,000 after buying an additional 12,682 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Health Catalyst in the fourth quarter valued at approximately $29,000. Finally, Virtu Financial LLC purchased a new position in shares of Health Catalyst during the fourth quarter worth approximately $110,000. Institutional investors and hedge funds own 85.00% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wells Fargo & Company decreased their price target on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a research note on Tuesday, January 21st. Piper Sandler lowered their price target on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a report on Tuesday, February 11th. Canaccord Genuity Group reduced their price objective on Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, January 21st. KeyCorp raised Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research report on Wednesday, January 8th. Finally, Citigroup dropped their target price on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Health Catalyst currently has a consensus rating of "Moderate Buy" and an average price target of $9.27.

Remove Ads

Health Catalyst Price Performance

Shares of NASDAQ:HCAT traded up $0.12 on Wednesday, reaching $4.45. 441,111 shares of the company were exchanged, compared to its average volume of 615,174. The company has a 50-day moving average of $4.98 and a 200-day moving average of $6.80. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $312.44 million, a price-to-earnings ratio of -3.30 and a beta of 1.41. Health Catalyst, Inc. has a 1-year low of $3.76 and a 1-year high of $9.24.

Insider Buying and Selling

In related news, insider Linda Llewelyn sold 6,442 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the transaction, the insider now directly owns 92,260 shares of the company's stock, valued at $535,108. This trade represents a 6.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the sale, the chief operating officer now owns 216,250 shares in the company, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,530 shares of company stock valued at $299,572. Corporate insiders own 2.50% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.